Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia

References

• Abshagen U., Bablok W., Koch K., Lang P. D., Schmidt H. A. E., Senn M., Stork H. Disposition kinetics of bezafibrate in man. Eur. J. Clin. Pharmacol 1979; 16: 311. Abshagen U., Bablok W., Koch K., Lang P. D., Schmidt H. A. E., Senn M., Stork H. Disposition kinetics of bezafibrate in man. Eur. J. Clin. Pharmacol 1979; 16: 31
   PubMed Web of Science ®Google Scholar
• Bolzano K., Krempler F., Schellenberg B., Schlierf G. Comparative investigation of bezafibrate and clofibrate in patients with hyperlipoproteinaemia Type IIb and IV. “Lipo-proteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 170–1712. Bolzano K., Krempler F., Schellenberg B., Schlierf G. Comparative investigation of bezafibrate and clofibrate in patients with hyperlipoproteinaemia Type IIb and IV. “Lipo-proteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 170–171
   Google Scholar
• Committee of Principal Investigators. A co-operative trial in the prevention of ischaemic heart disease using clofibrate. Br. Heart J 1978; 40: 1079–11183. Committee of Principal Investigators. A co-operative trial in the prevention of ischaemic heart disease using clofibrate. Br. Heart J 1978; 40: 1079–1118
   Google Scholar
• Committee of Principal Investigators. WHO co-operative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol; mortality follow-up. Lancet 1980; 2: 379–3854. Committee of Principal Investigators. WHO co-operative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol; mortality follow-up. Lancet 1980; 2: 379–385
   PubMed Web of Science ®Google Scholar
• Cooper J., Geizerova H., Oliver M. F. Clofibrate and gallstones. Lancet 1975; 1: 10835. Cooper J., Geizerova H., Oliver M. F. Clofibrate and gallstones. Lancet 1975; 1: 1083
   PubMed Web of Science ®Google Scholar
• Dawber T. R., Kannel W. B., Revotskie N., Kagan A. Epidemiology of coronary heart disease—the Framingham enquiry. Proc. R. Soc. Med 1962; 55: 265–2716. Dawber T. R., Kannel W. B., Revotskie N., Kagan A. Epidemiology of coronary heart disease—the Framingham enquiry. Proc. R. Soc. Med 1962; 55: 265–271
   PubMedGoogle Scholar
• Dick T. B. S., Stone M. C. Prevalence of three major risk factors in random samples of men and women and in patients with ischaemic heart disease. Br. Heart J 1978; 40: 617–6267. Dick T. B. S., Stone M. C. Prevalence of three major risk factors in random samples of men and women and in patients with ischaemic heart disease. Br. Heart J 1978; 40: 617–626
   PubMedGoogle Scholar
• Doyle J. T., Heslin A. S., Killeboe H. E., Formal P. F. Early diagnosis of ischaemic heart disease. N. Engl. J. Med 1959; 261: 1096–11018. Doyle J. T., Heslin A. S., Killeboe H. E., Formal P. F. Early diagnosis of ischaemic heart disease. N. Engl. J. Med 1959; 261: 1096–1101
   PubMed Web of Science ®Google Scholar
• Kaffarnik H., Schneider J., Schubotz R., Hausmann L., Mühlfellner O., Mühlfellner G. Effect of one year's treatment with bezafibrate in lipids and glucose tolerance in patients with various types of hyperlipoproteinaemia. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 163–1699. Kaffarnik H., Schneider J., Schubotz R., Hausmann L., Mühlfellner O., Mühlfellner G. Effect of one year's treatment with bezafibrate in lipids and glucose tolerance in patients with various types of hyperlipoproteinaemia. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 163–169
   Google Scholar
• Keys A., Taylor H. L., Blackburn H., Brozek J., Anderson J. T., Simonson E. Coronary heart disease among Minnesota business and professional men followed 15 years. Circulation 1963; 28: 381–39510. Keys A., Taylor H. L., Blackburn H., Brozek J., Anderson J. T., Simonson E. Coronary heart disease among Minnesota business and professional men followed 15 years. Circulation 1963; 28: 381–395
   PubMed Web of Science ®Google Scholar
• Lageder H., Irsigler K. Double-blind investigation comparing bezafibrate and clofibrate in patients with hyperlipoproteinaemia Type IIb and IV. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 133–13811. Lageder H., Irsigler K. Double-blind investigation comparing bezafibrate and clofibrate in patients with hyperlipoproteinaemia Type IIb and IV. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 133–138
   Google Scholar
• Lang P. D., Holler H. D., Vollmar J. Tolerance of one year's treatment with bezafibrate in patients with hyperlipoproteinaemia. “Diet and Drugs in Atherosclerosis”, G. Noseda, B. Lewis, R. Paoletti. Rowe Press, New York 1980; 137–14212. Lang P. D., Holler H. D., Vollmar J. Tolerance of one year's treatment with bezafibrate in patients with hyperlipoproteinaemia. “Diet and Drugs in Atherosclerosis”, G. Noseda, B. Lewis, R. Paoletti. Rowe Press, New York 1980; 137–142
   Google Scholar
• Morris J. N., Kagan A., Pattison D. C., Gardner M. J., Raffle P. A. B. Incidence and prediction of ischaemic heart disease in London busmen. Lancet 1966; 2: 553–55913. Morris J. N., Kagan A., Pattison D. C., Gardner M. J., Raffle P. A. B. Incidence and prediction of ischaemic heart disease in London busmen. Lancet 1966; 2: 553–559
   PubMed Web of Science ®Google Scholar
• Noseda G., Fragiacomo C., Weidmann P., Bachmann C. Therapeutische Wirksamkeit von Bezafibrat bei Hyperlipoproteinamien verschiedenen Typs. Schweiz. Med. Wochenschr 1980; 110: 1875–187714. Noseda G., Fragiacomo C., Weidmann P., Bachmann C. Therapeutische Wirksamkeit von Bezafibrat bei Hyperlipoproteinamien verschiedenen Typs. Schweiz. Med. Wochenschr 1980; 110: 1875–1877
   PubMedGoogle Scholar
• Olsson A. G. Effect of bezafibrate on lipids and lipoproteins in patients with hyperlipoproteinaemia Type IIa and IV on long term treatment. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock. Baden-Baden. 1980; 170–17115. Olsson A. G. Effect of bezafibrate on lipids and lipoproteins in patients with hyperlipoproteinaemia Type IIa and IV on long term treatment. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock. Baden-Baden. 1980; 170–171
   Google Scholar
• Olsson A. G., Lang P. D. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 1978; 31: 429–43316. Olsson A. G., Lang P. D. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 1978; 31: 429–433
   PubMed Web of Science ®Google Scholar
• Olsson A. G., Roessner S., Walldius G., Carlson L. A., Lang P. D. Effect of BM 15-075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 1977; 27: 279–28717. Olsson A. G., Roessner S., Walldius G., Carlson L. A., Lang P. D. Effect of BM 15-075 on lipoprotein concentrations in different types of hyperlipoproteinaemia. Atherosclerosis 1977; 27: 279–287
   PubMed Web of Science ®Google Scholar
• Pertsemlidis D., Panveliwalla D., Ahrens E. H. Effects of clofibrate and an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 1974; 66: 565–57318. Pertsemlidis D., Panveliwalla D., Ahrens E. H. Effects of clofibrate and an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 1974; 66: 565–573
   PubMed Web of Science ®Google Scholar
• Reddy J. K., Azarnoff D. L., Hignite C. E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980; 283: 397–39819. Reddy J. K., Azarnoff D. L., Hignite C. E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 1980; 283: 397–398
   PubMed Web of Science ®Google Scholar
• Schmidt F. H., Stegmeier K., Stork H., Endele R., Koch K. Pharmacokinetics and metabolism of bezafibrate in animals. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schqttler. Gerhard Witzstrock, Baden-Baden. 1980; 101–10420. Schmidt F. H., Stegmeier K., Stork H., Endele R., Koch K. Pharmacokinetics and metabolism of bezafibrate in animals. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schqttler. Gerhard Witzstrock, Baden-Baden. 1980; 101–104
   Google Scholar
• Stamler J., Schoenberger J. A., Lindberg H. A., Shekelle R., Stoker J. M., Epstein M. B., DeBoer L., Stamler R., Restivo R., Gray D., Cain W. Detection of susceptibility to coronary disease. Bull. N. Y. Acad. Med 1969; 45: 1306–132521. Stamler J., Schoenberger J. A., Lindberg H. A., Shekelle R., Stoker J. M., Epstein M. B., DeBoer L., Stamler R., Restivo R., Gray D., Cain W. Detection of susceptibility to coronary disease. Bull. N. Y. Acad. Med 1969; 45: 1306–1325
   PubMedGoogle Scholar
• Stegmeier K., Stork H., Lenz H., Leuschner F., Liede V. Pharmacology and mode of action of bezafibrate in animals. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 768222. Stegmeier K., Stork H., Lenz H., Leuschner F., Liede V. Pharmacology and mode of action of bezafibrate in animals. “Lipoproteins and Coronary Heart Disease”, H. Greten, P. D. Lang, G. Schettler. Gerhard Witzstrock, Baden-Baden. 1980; 7682
   Google Scholar
• Stone M. C., Thorpe J. M., Mills G. L., Dick T. B. S. Comparison of membrane filtration and nephelometry with analytical ultracentrifugation for the quantitative analysis of low density lipoprotein fractions. Clin. Chim. Acta 1970; 30: 809–82823. Stone M. C., Thorpe J. M., Mills G. L., Dick T. B. S. Comparison of membrane filtration and nephelometry with analytical ultracentrifugation for the quantitative analysis of low density lipoprotein fractions. Clin. Chim. Acta 1970; 30: 809–828
   PubMed Web of Science ®Google Scholar
• Symposium on Atromid. Atherosclerosis 1963; 3: 347–75324. Symposium on Atromid. Atherosclerosis 1963; 3: 347–753
   Google Scholar
• Tibblin G. Risk factors in coronary heart disease. “Thrombosis and Coronary Heart Disease”, P. I. Halenen, A. Louhija. Karger, Basle 1970; 4: 123–13025. Tibblin G. Risk factors in coronary heart disease. “Thrombosis and Coronary Heart Disease”, P. I. Halenen, A. Louhija. Karger, Basle 1970; 4: 123–130
   Google Scholar